SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

SELLAS Life Sciences Group Inc.

Nanophase Technologies Corp (($SLSN)) has held its Q4 earnings call. Read on for the main highlights of the call. Nanophase Technologies Corp struc...

Nanophase’s Earnings Call: Record Sales, Margin Reset

In a report released on March 31, Matteo Bonizzoni from Kepler Capital maintained a Buy rating on SOL SPA, with a price target of €56.50. The compa...

Kepler Capital  Sticks to Its Buy Rating for SOL SPA (0NJP)

Solstice Minerals Limited ( ($AU:SLS) ) has provided an update. Solstice Minerals Limited has applied to the ASX for quotation of 10,797,045 new or...

Solstice Minerals Seeks ASX Quotation for 10.8 Million New Shares

Global Surfaces Limited ( ($IN:GSLSU) ) has issued an update. Global Surfaces Limited has disclosed an internal equity transaction involving an off...

Global Surfaces Clarifies 2% Promoter Group Share Transfer After Trust Dissolution

Solstice Minerals Limited ( ($AU:SLS) ) has issued an update. Solstice Minerals Limited has disclosed that Treasury Services Group Pty Ltd, as trus...

Nero Resource Fund Ceases to Be Substantial Holder in Solstice Minerals

Solstice Minerals Limited ( ($AU:SLS) ) has issued an update. Solstice Minerals Limited has applied to the ASX for quotation of 135,823 additional ...

Solstice Minerals Seeks Quotation for Additional ASX Shares

The latest announcement is out from Solstice Minerals Limited ( ($AU:SLS) ). Solstice Minerals has reminded holders of its listed options, trading ...

Solstice Minerals Sets April 2026 Expiry for Listed Options

Canaccord Genuity analyst Paul Howard CFA maintained a Buy rating on Solstice Minerals Limited on March 17 and set a price target of A$1.85. Howard...

Canaccord Genuity Reaffirms Their Buy Rating on Solstice Minerals Limited (SLS)

In a report released yesterday, Sam Crittenden from RBC Capital maintained a Buy rating on Solaris Resources, with a price target of C$20.00. Accor...

Market Cap	$1.63B	P/E Ratio	N/A
52W High	$6.14	52W Low	$0.95
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	28.0%	52W Position	73.9%
Overall Score	50	Value Score	40
Quality Score	--	Technical Score	60

EPS Current Est	$-0.29	EPS Next Est	$NA
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SLS	$4.79	+6.10%	3.42M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SLS	$4.79	+6.1%	3.42M
3
4
5
6

SLS

SLS

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get SELLAS Life Sciences Group Inc. Data in Excel

Get SELLAS Life Sciences Group Inc. Data in Excel